Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model.

Bakir M, Standaert B, Turel O, Bilge ZE, Postma M.

Vaccine. 2013 Jan 30;31(6):979-86. doi: 10.1016/j.vaccine.2012.11.071. Epub 2012 Dec 6.

PMID:
23219433
2.

Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.

Rheingans RD, Antil L, Dreibelbis R, Podewils LJ, Bresee JS, Parashar UD.

J Infect Dis. 2009 Nov 1;200 Suppl 1:S16-27. doi: 10.1086/605026. Review.

PMID:
19817595
3.

Economics of rotavirus gastroenteritis and vaccination in Europe: what makes sense?

Rheingans RD, Heylen J, Giaquinto C.

Pediatr Infect Dis J. 2006 Jan;25(1 Suppl):S48-55. Review.

PMID:
16397429
4.

Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries.

Plosker GL.

Pharmacoeconomics. 2011 May;29(5):439-54. doi: 10.2165/11207130-000000000-00000. Review.

PMID:
21504245
5.

Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world.

Postma MJ, Jit M, Rozenbaum MH, Standaert B, Tu HA, Hutubessy RC.

BMC Med. 2011 Jul 8;9:84. doi: 10.1186/1741-7015-9-84. Review.

6.

A critical literature review of health economic evaluations of rotavirus vaccination.

Aballéa S, Millier A, Quilici S, Caroll S, Petrou S, Toumi M.

Hum Vaccin Immunother. 2013 Jun;9(6):1272-88. doi: 10.4161/hv.24253. Epub 2013 Apr 9. Review.

7.

Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Grimwood K, Lambert SB, Milne RJ.

Paediatr Drugs. 2010 Aug 1;12(4):235-56. doi: 10.2165/11537200-000000000-00000. Review.

PMID:
20593908
8.

Rotavirus vaccines and vaccination in Latin America.

Linhares AC, Bresee JS.

Rev Panam Salud Publica. 2000 Nov;8(5):305-31. Review.

PMID:
11190969
9.

Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings.

Ehrenkranz P, Lanata CF, Penny ME, Salazar-Lindo E, Glass RI.

Rev Panam Salud Publica. 2001 Oct;10(4):240-8. Review.

PMID:
11715170
10.

Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines.

Widdowson MA, Steele D, Vojdani J, Wecker J, Parashar U.

J Infect Dis. 2009 Nov 1;200 Suppl 1:S1-8. doi: 10.1086/605061. Review.

PMID:
19817589
11.

Systematic review of studies on rotavirus disease cost-of-illness and productivity loss in Latin America and the Caribbean.

Takemoto ML, Bahia L, Toscano CM, Araujo DV.

Vaccine. 2013 Jul 2;31 Suppl 3:C45-57. doi: 10.1016/j.vaccine.2013.05.031. Review.

PMID:
23777691
12.

Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Plosker GL.

Pharmacoeconomics. 2011 Nov;29(11):989-1009. doi: 10.2165/11207210-000000000-00000. Review.

PMID:
21988293
13.

Overcoming perceptions of financial barriers to rotavirus vaccine introduction in Asia.

Nelson EA, de Quadros CA, Santosham M, Parashar UD, Steele D.

Hum Vaccin Immunother. 2013 Nov;9(11):2418-26. Epub 2013 Aug 16. Review.

14.

Rotavirus vaccines: development, current issues and future prospects.

Cunliffe NA, Bresee JS, Hart CA.

J Infect. 2002 Jul;45(1):1-9. Review.

PMID:
12217724
15.

Do current cost-effectiveness analyses reflect the full value of childhood vaccination in Europe? A rotavirus case study.

Brüggenjürgen B, Lorrot M, Sheppard FR, Rémy V.

Hum Vaccin Immunother. 2014;10(8):2290-4. doi: 10.4161/hv.29090. Review.

16.

Rotavirus vaccination in developing countries.

Babji S, Kang G.

Curr Opin Virol. 2012 Aug;2(4):443-8. doi: 10.1016/j.coviro.2012.05.005. Epub 2012 Jun 13. Review.

PMID:
22698800
17.

Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples.

Postma MJ, Westra TA, Quilici S, Largeron N.

Expert Rev Vaccines. 2013 May;12(5):555-65. doi: 10.1586/erv.13.36. Review.

PMID:
23659302
18.

Assessing the impact of vaccination programmes on burden of disease: Underlying complexities and statistical methods.

Mealing N, Hayen A, Newall AT.

Vaccine. 2016 Jun 8;34(27):3022-9. doi: 10.1016/j.vaccine.2016.04.014. Epub 2016 May 6. Review.

PMID:
27156635

Supplemental Content

Support Center